Funding for this research was provided by:
Carl Zeiss Meditec AG (Unrestricted Grant)
Text and Data Mining valid from 2019-05-09
Received: 7 May 2018
Accepted: 1 May 2019
First Online: 9 May 2019
Ethics approval and consent to participate
: This study was approved by the local ethics committee (Medical Ethics Commission II of the Faculty of Medicine Mannheim, University of Heidelberg, 2013-593 N-MA) and the Federal Office of Radiation Protection (Z5–22462/2–2013-116). Written informed consent is obtained from all patients participating in this study.
: Not applicable.
: FB, UO, ESp, YAM, FS and SC are on the Carl Zeiss Meditec AG speaker’s bureau. GW received travel support from Carl Zeiss Meditec AG. FW is an advisor, consultant and/or speaker for Celgene GmbH, Roche Pharma AG, Eli Lilly and Company, Ipsen Pharma GmbH, receives travel and research grants from Carl Zeiss Meditec AG and Elekta AB, is on the Carl Zeiss Meditec AG speaker’s bureau and holds patents related with Carl Zeiss Meditec AG. FG serves as consultant and speaker for Carl Zeiss Meditec AG (the manufacturer of the device used for IORT in this trial), NOXXON Pharma AG, Merck Serono GmbH, Roche Pharma AG, Siemens Healthcare Diagnostics GmbH and holds patents related with Carl Zeiss Meditec AG.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.